Neonatal Abstinence Syndrome
Pregnant women receiving medication therapy for addiction can be prescribed higher doses of buprenorphine without increasing the risk or severity of neonatal abstinence syndrome.
Methadone may be superior to morphine for reducing hospital length of stay and length of drug treatment in infants with neonatal abstinence syndrome.
Methadone exposure in utero was shown to increase the risk for neonatal abstinence syndrome compared with buprenorphine exposure.
The infants of women taking opioids concomitantly with psychotropic medications were found to have a substantially heightened risk of neonatal drug withdrawal.
In infants with neonatal abstinence syndrome, sublingual buprenorphine reduced the duration of treatment and decreased the length of hospital stay.
Sublingual buprenorphine is associated with shorter duration of treatment than oral morphine for infants with neonatal abstinence syndrome.
The article reviews the epidemiology, clinical features, outcomes, prevention strategies, risk identification and management NAS.
Children with neonatal abstinence syndrome may be more likely to perform poorly in school.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds